Medivation, Inc. is a biopharmaceutical company focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company selects technologies for development that can enter human studies within 12-18 months. It develops technologies without regard to therapeutic indication or therapeutic modality, such as small molecules, biologics and medical devices. The Company is engaged in various clinical trials. The Company�s PROSPER is a Phase III clinical trial. The Company�s TERRAIN trial and the STRIVE trial are two randomized, double-blind Phase II trials evaluating enzalutamide head-to-head versus bicalutamide in pre-chemotherapy CRPC patients. The Company�s PLATO is a Phase IV clinical trial. The Company and Astellas expanded the clinical development of enzalutamide to include breast cancer as a new indication.